Cellectar Biosciences announced updated data from its Phase 2b CLOVER WaM trial showing durable responses in patients with relapsed or refractory Waldenström macroglobulinemia treated with iopofosine I 131. The data suggest greater benefit when used earlier in treatment. The company will present these findings and the design of its Phase 3 confirmatory trial at the ASH Annual Meeting in December 2026. Site activation for the Phase 3 trial is underway with first patient dosing expected in Q1 2027, and an FDA accelerated approval filing targeted for the first half of 2027.
Cellectar Biosciences data update provides context for health sector trading. For readers following health stocks, 127 of 150 US health-sector stocks rose while 19 fell as of Nov 04, 2026 20:41 WIB. Notable movers include TLRY at USD 2.78 with a 4.91% increase and 96% sell activity, ALC at USD 75.51 up 4.34% with 91% sell activity, and SYRE at USD 95.00 down 4.30% with a typical hold time of 5 days on Pluang.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
